ZURA BIO LIMITED Increase (Decrease) in Other Noncurrent Assets
ZURA BIO LIMITED (ZURA) reported Increase (Decrease) in Other Noncurrent Assets of -$1.51 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-11
- ZURA BIO LIMITED increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $0.00.
- ZURA BIO LIMITED increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $814.00K.
- ZURA BIO LIMITED increase (decrease) in other noncurrent assets for fiscal 2025 was $814.00K, a 16.62% increase from fiscal 2024.
- ZURA BIO LIMITED increase (decrease) in other noncurrent assets for fiscal 2024 was $698.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.51K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $814.00K derived: sum of 2 quarters · filed 2026-03-19 | $814.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | $814.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $814.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $698.00K 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |